SCIEX launches Echo MS+ System to enhance drug discovery through advanced mass spectrometry

SCIEX, a world-renowned leader in life science analytical technologies, introduced the Echo MS+ system at the Society for Laboratory Automation and Screening (SLAS) 2024 conference. This groundbreaking system integrates proprietary Acoustic Ejection Mass Spectrometry technology and Open Port Interface (OPI) sampling with the advanced capabilities of either the SCIEX ZenoTOF 7600 or Triple Quad 6500+ system. The Echo MS+ system is designed to deliver precise qualitative and quantitative results across a broad panel of robust high-throughput screening workflows for both small and large molecules.

The Echo MS+ system addresses the critical challenges faced in high-throughput screening applications for drug discovery, notably reducing the need for extensive method development. It achieves this through introducing new, flexible workflows that utilize high-resolution mass spectrometry, thereby offering improved selectivity and sensitivity over other analytical tools. This advancement significantly enhances the speed of analysis, data quality, and efficiency by minimizing sample and reagent consumption.

Echo MS+ System: Pioneering Precision in Drug Discovery with SCIEX’s Latest Technology. Photo courtesy of Business Wire.

According to Jose Castro-Perez, Vice President of Product Management at SCIEX, integrating this technology with high-resolution mass spectrometry will enable the development of novel workflows for a diverse range of molecule types. This innovation is poised to accelerate the drug discovery process by facilitating quicker and more reliable decision-making in hit identification and lead optimization, thus minimizing the occurrence of false positive or false negative results.

Looking ahead, SCIEX plans to collaborate with customers at its global Echo® MS Center of Excellence to further develop innovative workflows for the Echo® MS+ system. The aim is to tackle unmet analytical needs with this disruptive technology, reinforcing SCIEX’s commitment to advancing scientific discovery and drug development.

The introduction of the Echo MS+ system by SCIEX at SLAS 2024 marks a significant milestone in the field of drug discovery and development. By combining acoustic ejection mass spectrometry with high-resolution capabilities, SCIEX is not only addressing existing challenges in high-throughput screening but also paving the way for future innovations. This technology stands to drastically reduce the time and resources required in the early stages of drug development, offering a promising outlook for the pharmaceutical industry.